The company projects initial revenue generation from its Sildenafil Cream formulation in Q4 2025, backed by its 503B compounding strategy. Daré plans to provide updates in Q2 2025 on strategic ...

Since 2022, four GLP-1 drugs, including those indicated for weight loss, have been on FDA’s drug shortage list due to extraordinarily high patient demand. The shortage has, in turn, resulted in ...

Please provide your email address to receive an email when new articles are posted on . FDA warned of potential serious risks when using compounded topical finasteride. There are no FDA-approved ...

The Food and Drug Administration said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of tirzepatide — the active ingredient in Eli Lilly’s ...

Compounded medications are not FDA-approved. This means they haven’t undergone the same rigorous testing for safety and effectiveness. The FDA advises against using compounded versions unless approved ...